Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8461 to 8475 of 9043 results

  1. Durvalumab for untreated metastatic non-small-cell lung cancer with no EGFR- or ALK-positive mutations [ID1331]

    Discontinued Reference number: GID-TA10318

    Technology appraisal guidance
    Discontinued

  2. Nivolumab with ipilimumab for treating squamous cell carcinoma of the head and neck [ID1355]

    Discontinued Reference number: GID-TA10321

    Technology appraisal guidance
    Discontinued

  3. Lifitegrast for treating dry eye disease [ID1229]

    Discontinued Reference number: GID-TA10196

    Technology appraisal guidance
    Discontinued

  4. Durvalumab with tremelimumab for untreated non-small-cell lung cancer with no EGFR- or ALK-positive mutations [ID1143]

    Discontinued Reference number: GID-TA10186

    Technology appraisal guidance
    Discontinued

  5. Nivolumab for small-cell lung cancer after platinum-based chemotherapy [ID1126]

    Discontinued Reference number: GID-TA10158

    Technology appraisal guidance
    Discontinued

  6. Temozolomide for the treatment of advanced and metastatic melanoma [ID316]

    Discontinued Reference number: GID-TAG401

    Technology appraisal guidance
    Discontinued

  7. Nilotinib for the first line treatment of chronic myeloid leukaemia [ID79]

    Discontinued Reference number: GID-TAG408

    Technology appraisal guidance
    Discontinued

  8. Prostate cancer (prevention) - dutasteride [ID75]

    Discontinued Reference number: GID-TAG409

    Technology appraisal guidance
    Discontinued

  9. Sunitinib in combination with capecitabine for the treatment of advanced and/or metastatic breast cancer [ID319]

    Discontinued Reference number: GID-TAG410

    Technology appraisal guidance
    Discontinued

  10. Prostate cancer (hormone refractory) - atrasentan [ID390]

    Discontinued Reference number: GID-TAG379

    Technology appraisal guidance
    Discontinued

  11. Atrial fibrillation - idraparinux sodium [ID375]

    Discontinued Reference number: GID-TAG383

    Technology appraisal guidance
    Discontinued

  12. Psoriatic arthritis (moderate to severe) - leflunomide [ID391]

    Discontinued Reference number: GID-TAG385

    Technology appraisal guidance
    Discontinued

  13. Lapatinib for breast cancer (for use in women with previously treated advanced or metastatic breast cancer) [ID20]

    Discontinued Reference number: GID-TAG387

    Technology appraisal guidance
    Discontinued

  14. Clostridium difficile associated diarrhoea - tolevamer [ID378]

    Discontinued Reference number: GID-TAG389

    Technology appraisal guidance
    Discontinued

  15. Intensity modulated radiotherapy for breast cancer [ID16]

    Discontinued Reference number: GID-TAG390

    Technology appraisal guidance
    Discontinued